A systematic study of oligodendrocyte growth factors as candidates for genetic susceptibility to MS

Neurology

Volumn 51, Issue 3, 1998, Pages 748-753

  Mertens, C ^a   Brassat, D ^a,c   Reboul, J ^a   Eichenbaum Voline, S ^b   Vuillemin Azais, C ^e   Cournu, I ^a   Babron, M C ^b   Semana, G ^d   Edan, G ^d   Clanet, M ^c   Clerget Darpoux, F ^b   Baron Van Evercooren, A ^a   Lyon Caen, O ^a   Liblau, R ^a   Fontaine, Bertrand ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c CHU PURPAN   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^e Hop de la Salpêtrière ^*

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; LEUKOCYTE ANTIGEN; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DATA ANALYSIS; DEMYELINATION; DNA FLANKING REGION; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; MULTIGENE FAMILY; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PRIORITY JOURNAL; RECEPTOR GENE; STEM CELL;

EID: 0031722260     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.3.748     Document Type: Article

References (41)

1. Ebers GC, Sadovnick AD. The role of genetic factors in multiple sclerosis susceptibility. J Neuroimmunol 1994;54:1-17.
2. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Nature 1995;377:150-151.
3. Kuokkanen S, Sundvall M, Terwilliger JD, et al. A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2. Nat Genet 1996; 13:477-480.
4. Jersild C, Fog T, Hansen GS, Thomsen M, Sverjgaard A, Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973;2:1221-1225.
5. Voskuhl RR, Goldstein AM, Simonis T, Davey R, McFarland HF. DR2/DQw1 inheritance and haplotype sharing in affected siblings from multiple sclerosis families. Ann Neurol 1996;39: 804-807.
6. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996;6:259-274.
7. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994;117: 1311-1322.
8. McMorris FA, McKinnon RD. Regulation of oligodendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating diseases. Brain Pathol 1996;6:313-329.
9. Woodruff RH, Franklin RJ. Growth factors and remyelination in the CNS. Histol Histopathol 1997;12:459-466.
10. Raff MC, Lillien LE, Richardson WD, Burne JF, Noble MD. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 1988;333:562-565.
11. Redwine JM, Blinder KL, Armstrong RC. In situ expression of fibroblast growth factor receptors by oligodendrocyte progenitors and oligodendrocytes in adult mouse central nervous system. J Neurosci Res 1997;50:229-237.
12. McKay JS, Blakemore WF, Franklin RJ. The effects of the growth factor antagonist, trapidil, on remyelination in the CNS. Neuropathol Appl Neurobiol 1997;23:50-58.
13. Osterhout DJ, Ebner S, Xu J, Ornitz DM, Zazanis GA, McKinnon RD. Transplanted oligodendrocyte progenitor cells expressing a dominant-negative FGF receptor transgene fail to migrate in vivo. J Neurosci 1997;17:9122-9132.
14. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989;58: 575-606.
15. McMorris FA, Mozell RL, Carson MJ, Shinar Y, Meyer RD, Marcetti N. Regulation of oligodendrocyte development and central nervous system myelination by insulin-like growth factors. Ann NY Acad Sci 1993;692:321-334.
16. Komoly S, Hudson LD, Webster H, Bondy CA. Insulin-like growth factor 1 gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci USA 1992;89:1894-1898.
17. Yao DL, Liu X, Hudson LD, Webster HD. Insulin-like growth factor-1 given subcutaneously reduces clinical deficits, decreases lesion severity, and up-regulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis. Life Sci 1996;58:1301-1306.
18. Barres BA, Raff MC, Gaese F, Bartke I, Dechant G, Barde YA. A crucial role for neurotrophin-3 in oligodendrocyte development. Nature 1994;367:371-375.
19. Canoll P, Mussachio JM, Hardy R, Reynolds R, Marchianni MA, Salzer JL. GGF/neuregulin is a neuronal signal that promotes the proliferation and survival, and inhibits the differentiation of oligodendrocyte progenitors. Neuron 1996;17:229-243.
20. McKinnon RD, Piras G, Ida JA, Dubois-Dalcq M. A role for TGFb in oligodendrocyte differentiation. J Cell Biol 1993;121: 1397-1407.
21. Goodkin DE, Doolittle TH, Hauser SL, Ransohoff RM, Roses AD, Rudick RA. Diagnostic criteria for multiple sclerosis research involving multiply affected families. Arch Neurol 1991; 48:805-807.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
23. Li X, Jaye M, Crumley G, Jabs EW. Dinucleotide repeat polymorphism in the human fibroblast growth factor acidic (FGFA) gene on chromosome 5. Hum Mol Genet 1992;1:216.
24. Polymeropoulos MH, Rath DS, Xiao H, Merril CR. Dinucleotide repeat polymorphism at the human gene for insulin-like growth factor 1 (IGF1). Nucleic Acids Res 1991;19:5797.
25. Hattori M, Kuwata S, Fukuda R, et al. Dinucleotide repeat polymorphism in the promoter region of neurotrophin-3 gene (NT3). Hum Mol Genet 1993;2:1511.
26. Thomas W, Rubenstein M, Goto M, Drayna D. A genetic analysis of the Werner syndrome region on human chromosome 8p. Genomics 1993;16:685-690.
27. Chi DD, Hing AV, Helms C, Steinbrueck T, Mishra SK, Donis-Keller H. Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (EGFR) and pro-alpha 2 (I) collagen (COL1A2). Hum Mol Genet 1992; 1:135.
28. Abraham JA, Whang JL, Tumolo A. Human basic fibroblast growth factor: nucleotide sequence, genomic organization. EMBO J 1986;5:2523-2528.
29. Derynck R, Jarrett JA, Chen EY, et al. Human transforming growth factor-B complementary DNA sequence and expression in normal and transformed cells. Nature 1985;316:701-705.
30. Johnson DW, Qumsiyeh M, Benkhalifa M, Marchuk DA. Assignment of human transforming growth factor-beta type I and type III receptor genes (TGFBR1 and TGFBR3) to 9q33-q34 and 1p32-p33, respectively. Genomics 1995;28:356-357.
31. Humphries DE, Bloom BB, Fine A, Goldstein RH. Structure and expression of the promoter for the human type II transforming growth factor-beta receptor. Biochem Biophys Res Commun 1994;203:1020-1027.
32. Risch N. Linkage strategies for genetically complex traits. III. The effect of marker polymorphism on analysis of affected relative pairs. Am J Hum Genet 1990;46:242-253.
33. Kruglyak L, Lander ES. Complete multipoint sibpair analysis of qualitative and quantitative traits. Am J Hum Genet 1995; 57:439-454.
34. Holmans P. Asymptomatic properties of affected-sib-pair linkage analysis. Am J Hum Genet 1993;52:362-374.
35. Yaouanq J, Semana G, Eichenbaum S, et al. Evidence for linkage disequilibrium between HLA-DRB1 gene and multiple sclerosis. Science 1997;276:664-665.
36. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-261.
37. Sawcer S, Jones HB, Feakes R, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genet 1996;13:464-468.
38. The Multiple Sclerosis Genetics Group. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nature Genet 1996;13:469-471.
39. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nat Genet 1996;13:472-476.
40. Eichenbaum-Voline S, Babron MC, Prum B, Clerget-Darpoux F. The maximum likelihood score and the exclusion test. Genet Epidemiol 1997;14:514. Abstract.
41. Bennett ST, Todd JA. Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet 1996; 30:343-370.